Enanta Pharmaceuticals Inc (ENTA)
12.62
-0.31
(-2.40%)
USD |
NASDAQ |
May 10, 16:00
12.62
0.00 (0.00%)
After-Hours: 20:00
Enanta Pharmaceuticals Enterprise Value: -26.76M for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | -26.76M |
| May 08, 2024 | -30.36M |
| May 07, 2024 | -23.17M |
| May 06, 2024 | 8.568M |
| May 03, 2024 | 20.63M |
| May 02, 2024 | -6.03M |
| May 01, 2024 | -13.43M |
| April 30, 2024 | -9.627M |
| April 29, 2024 | -19.99M |
| April 26, 2024 | -38.61M |
| April 25, 2024 | -36.28M |
| April 24, 2024 | -26.97M |
| April 23, 2024 | -22.11M |
| April 22, 2024 | -15.97M |
| April 19, 2024 | -18.51M |
| April 18, 2024 | -20.42M |
| April 17, 2024 | -4.126M |
| April 16, 2024 | 24.65M |
| April 15, 2024 | 41.36M |
| April 12, 2024 | 47.71M |
| April 11, 2024 | 54.05M |
| April 10, 2024 | 49.61M |
| April 09, 2024 | 55.53M |
| April 08, 2024 | 45.80M |
| April 05, 2024 | 48.98M |
| Date | Value |
|---|---|
| April 04, 2024 | 41.99M |
| April 03, 2024 | 53.21M |
| April 02, 2024 | 45.59M |
| April 01, 2024 | 59.77M |
| March 31, 2024 | 69.07M |
| March 28, 2024 | 32.23M |
| March 27, 2024 | 12.56M |
| March 26, 2024 | 0.2872M |
| March 25, 2024 | -42.24M |
| March 22, 2024 | -28.48M |
| March 21, 2024 | -27.64M |
| March 20, 2024 | -30.39M |
| March 19, 2024 | -40.12M |
| March 18, 2024 | -51.33M |
| March 15, 2024 | -36.52M |
| March 14, 2024 | -43.93M |
| March 13, 2024 | -31.66M |
| March 12, 2024 | -29.54M |
| March 11, 2024 | -18.12M |
| March 08, 2024 | -11.35M |
| March 07, 2024 | -4.579M |
| March 06, 2024 | -5.848M |
| March 05, 2024 | -18.54M |
| March 04, 2024 | -6.060M |
| March 01, 2024 | -12.41M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-197.65M
Minimum
Nov 13 2023
1.735B
Maximum
Nov 05 2021
650.89M
Average
662.53M
Median
Dec 13 2022
Enterprise Value Benchmarks
| Madrigal Pharmaceuticals Inc | 3.472B |
| Galectin Therapeutics Inc | 247.63M |
| Viking Therapeutics Inc | 7.882B |
| Akero Therapeutics Inc | 909.06M |
| 89bio Inc | 313.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.16M |
| Revenue (Quarterly) | 17.05M |
| Total Expenses (Quarterly) | 49.82M |
| EPS Diluted (Quarterly) | -1.47 |
| Profit Margin (Quarterly) | -182.7% |
| Earnings Yield | -49.45% |
| Normalized Earnings Yield | -49.45 |